Carbamates - Therapeutic use
Research News and Information

Sunday, November 22, 2009

Change in glucometer settings as a cause of sudden deterioration of glycemic control in type 2 diabetes.

29 Jun 2009 The subject matter of this case report is "sudden deterioration" of glycemic control in a thus far well-complying patient with type 2 diabetes. It describes possible impacts of glucometer technical failure associated with other unfavorable ... Read more...

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

8 Jun 2009 BACKGROUND: APV102002 was an open-label study comparing a dual-boosted HIV-1 protease inhibitor (PI) [fosamprenavir/lopinavir/ritonavir (FPV/LPV/RTV; 1400 mg/533 mg/133 mg twice daily)] and a high dose of FPV/RTV 1400 mg/100 mg twice daily ... Read more...

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

4 May 2009 OBJECTIVES: We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients. ... Read more...

Latest indexed articles for 'Carbamates - Therapeutic use'

These are the very latest articles for this heading:

• Change in glucometer settings as a cause of sudden deterioration of glycemic control in type 2 diabetes. 29 Jun 2009
• Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. 8 Jun 2009
• Favourable use of non-boosted fosamprenavir in patients treated with warfarin. 30 May 2009
• Metformin/Repaglinide (PrandiMet) for type 2 diabetes. 30 May 2009
• Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. 4 May 2009
• Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy. 29 Apr 2009
• Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. 30 Mar 2009
• Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. 30 Mar 2009
• Comment on: Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. 22 Mar 2009
• Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. 27 Feb 2009
• A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. 30 Jan 2009
• Plasmodium falciparum signal peptide peptidase is a promising drug target against blood stage malaria. 23 Jan 2009
• Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. 14 Jan 2009
• Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. 7 Jan 2009
• The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. 30 Dec 2008
• Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. 30 Dec 2008
• Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome. 30 Dec 2008
• Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania. 29 Dec 2008
• Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. 29 Nov 2008
• Four posters add to our knowledge of Lexiva. 29 Nov 2008

See a longer list of these articles.

Technical information about 'Carbamates'

Definition: Salts or esters of carbamic acid, H2NC(=O)OH, or of N-substituted carbamic acids: R2NC(=O)OR', (R' = hydrocarbyl or a cation). The esters are often called URETHANE or urethan, a usage that is strictly correct only for the ethyl esters. (From IUPAC [Internet]. International Union Of Pure And Applied Chemistry; c1995 [updated 2004 Jan 9; cited 2004 May 3]. Available from http://www.chem.qmul.ac.uk/iupac/class/oneN.html#35/).

Registry Number: 0

Descriptor UI: D002219

Alternative terms: Carbamates;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.241.081.251;

Online Note: use CARBAMATES to search TYBAMATE 1966-84 (as Prov 1966-72)

History Note: TYBAMATE was heading 1965-84 (Prov 1965-72)